MARKET

NSPR

NSPR

Inspiremd
NASDAQ
1.950
0.000
0.00%
After Hours: 1.950 0 0.00% 16:10 12/12 EST
OPEN
1.940
PREV CLOSE
1.950
HIGH
1.950
LOW
1.880
VOLUME
58.53K
TURNOVER
--
52 WEEK HIGH
3.798
52 WEEK LOW
1.590
MARKET CAP
82.62M
P/E (TTM)
-2.3228
1D
5D
1M
3M
1Y
5Y
1D
InspireMD Director Paul Stuka Reports Acquisition of Common Shares
Reuters · 3d ago
Weekly Report: what happened at NSPR last week (1201-1205)?
Weekly Report · 6d ago
Director’s Bold Move: Major Stock Purchase at InspireMD!
TipRanks · 12/06 02:05
BioCardia appoints Slosman to its Board of Directors
TipRanks · 12/03 13:16
Weekly Report: what happened at NSPR last week (1124-1128)?
Weekly Report · 12/01 09:34
Lake Street Reaffirms Their Buy Rating on InspireMD (NSPR)
TipRanks · 11/24 13:55
InspireMD announces publication of CREST-2 data in NEJM
TipRanks · 11/24 12:45
InspireMD CREST-2 Data Demonstrates Addition Of Stenting Improves Outcomes In Trial For Participants With Asymptomatic Carotid Stenosis
Benzinga · 11/24 12:34
More
About NSPR
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Webull offers InspireMD Inc stock information, including NASDAQ: NSPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NSPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NSPR stock methods without spending real money on the virtual paper trading platform.